SCHEMBL446809

SCHEMBL446809

NC(=O)c1ccnc(N)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.70
GABRD O14764 2/20 0.70
GABRA1 P14867 2/20 0.70
GABRB1 P18505 2/20 0.70
GABRG2 P18507 2/20 0.70
GABRB3 P28472 2/20 0.70
GABRA5 P31644 2/20 0.70
GABRA3 P34903 2/20 0.70
GABRA2 P47869 2/20 0.70
GABRB2 P47870 2/20 0.70
GABRA4 P48169 2/20 0.70
GABRE P78334 2/20 0.70
GABRA6 Q16445 2/20 0.70
GABRG1 Q8N1C3 2/20 0.70
GABRG3 Q99928 2/20 0.70
GABRQ Q9UN88 2/20 0.70
MKNK1 Q9BUB5 2/20 0.65
MKNK2 Q9HBH9 2/20 0.65
KDM5C P41229 2/20 0.53
KDM5B Q9UGL1 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL28800775 0.83 GABRP (0.56) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL220538 0.83 GABRP (1.00) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30705741 0.83 GABRP (1.00) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1159738 0.81 GABRP (0.68) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL22797869 0.81 GABRP (0.96) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL19586492 0.81 GABRP (0.68) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31661275 0.81 GABRP (0.68) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7038517 0.80 KDM5C (0.69) MKNK1MKNK2KDM5CKDM5BKDM4B
SCHEMBL14650210 0.80 MKNK1 (0.71) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL6227701 0.79 GABRP (0.66) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113994259-B Photosensitive resin composition, transfer film, cured film, laminate, and method for producing touch panel 富士胶片株式会社 2024-05-28 CN claimed
EP-2038264-B1 TETRAZOLE-SUBSTITUTED ARYLAMIDES HOFFMANN LA ROCHE (CH) 2016-10-26 EP claimed
CN-102633715-A Inhibitor of mitogen protein kinase p38 and preparation method of inhibitor WUXI ALLNATURE NUTRITION HEALTH CARE PRODUCT TECHNOLOGY CO LTD 2012-08-15 CN claimed
EP-1362054-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-11-19 EP claimed
WO-2002064599-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO claimed
EP-4644390-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-11-05 EP disclosed
CN-114621222-B 6-6 Fused bicyclic heteroaryl compounds and their use as LATS inhibitors 诺华股份有限公司 2024-12-17 CN disclosed
WO-2024140850-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-07-04 WO disclosed
CN-118063491-A Imide catalyst auxiliary agent, polyimide film and preparation method 中国科学院化学研究所 2024-05-24 CN disclosed
CN-115108976-B Method for preparing pyridine carboxamide by one-step oxidation amidation 大连理工大学 2023-10-24 CN disclosed
US-20230101819-A1 SMYD Inhibitors EPIZYME INC (US) 2023-03-30 US disclosed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP disclosed
WO-2002055501-A2 N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AMGEN INC (US) 2002-07-18 WO disclosed
US-5972975-A Substituted 2-aminopyridines as inhibitors of nitric oxide synthase MERCK & CO., INC. (US) 1999-10-26 US disclosed
WO-1996018616-A1 SUBSTITUTED 2-AMINOPYRIDINES AS INHIBITORS OF NITRIC OXIDE SYNTHASE MERCK & CO., INC. (US) 1996-06-20 WO disclosed
EP-0356234-B1 New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1994-05-11 EP disclosed
EP-0189678-B1 ELECTROCHEMICAL REDUCTIONS OF PYRIDINE CARBOXAMIDE BASES REILLY INDUSTRIES, INC. (US) 1991-11-06 EP disclosed
US-5047411-A Antiulcer Agents, H2-Receptor Antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-09-10 US disclosed
EP-0356234-A2 New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-02-28 EP disclosed
US-4695352-A Electrochemical reduction of pyridine carboxamide bases REILLY TAR & CHEMICAL CORPORATION (US) 1987-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230101819-A1 SMYD Inhibitors SMYD3, SMYD2, SMURF2 GABRP 3013/4885GABRD 3298/4885GABRA1 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.